Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

被引：0
|
作者：
Volkmann, Elizabeth R. [1 ]
Roth, Michael [1 ]
Elashoff, Robert [2 ]
Clements, Philip J. [1 ]
Furst, Daniel E. [1 ]
Khanna, Dinesh [3 ]
Goldin, Jonathan [4 ]
Tashkin, Donald [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Biomath, Los Angeles, CA 90095 USA
[3] Univ Michigan, Med, Ann Arbor, MI 48109 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1076
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CYCLOPHOSPHAMIDE VERSUS MYCOPHENOLATE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Volkmann, E.
    Tashkin, D.
    Clements, P.
    Roth, M.
    Furst, D.
    Khanna, D.
    Tseng, C-H.
    Arriola, E.
    Elashoff, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 821 - 821
  • [2] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Gkiouras, Konstantinos
    Grammatikopoulou, Maria G.
    Simopoulou, Theodora
    Daniil, Zoe
    Bogdanos, Dimitrios P.
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3379 - 3380
  • [3] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Konstantinos Gkiouras
    Maria G. Grammatikopoulou
    Theodora Simopoulou
    Zoe Daniil
    Dimitrios P. Bogdanos
    Clinical Rheumatology, 2021, 40 : 3379 - 3380
  • [4] Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Li, Ning
    Roth, Michael
    Khanna, Dinesh
    Hoffmann-Vold, Anna-Maria
    Clements, Philip J.
    Furst, Daniel E.
    Elashoff, Robert
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Mycophenolate Versus Placebo For The Treatment Of Systemic Sclerosis-Related Interstitial Lung Disease
    Tashkin, D. P.
    Volkmann, E.
    Roth, M. D.
    Li, N.
    Khanna, D.
    Furst, D.
    Elashoff, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] PROBING THE UNIQUE GENETIC AND ADVERSE EVENT SIGNATURES OF CYCLOPHOSPHAMIDE VERSUS MYCOPHENOLATE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Volkmann, E.
    Zagouras, P.
    Tashkin, D.
    Heck, S.
    Volkmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1128 - 1129
  • [7] Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis
    Ma, Xinyu
    Tang, Rui
    Luo, Mei
    Zeng, Zhuotong
    Shi, Yaqian
    Tang, Bingsi
    Xiao, Rong
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3185 - 3193
  • [8] Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis
    Xinyu Ma
    Rui Tang
    Mei Luo
    Zhuotong Zeng
    Yaqian Shi
    Bingsi Tang
    Rong Xiao
    Clinical Rheumatology, 2021, 40 : 3185 - 3193
  • [9] Systemic Sclerosis-Related Interstitial Lung Disease
    Dalal, Samay
    Fischer, Aryeh
    Swigris, Jeffrey J.
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2008, 4 (03) : 226 - 232
  • [10] Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease An Analysis of Scleroderma Lung Studies I and II
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Li, Ning
    Roth, Michael D.
    Khanna, Dinesh
    Hoffmann-Vold, Anna-Maria
    Kim, Grace
    Goldin, Jonathan
    Clements, Philip J.
    Furst, Daniel E.
    Elashoff, Robert M.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (07) : 1451 - 1460
12345